- Report
- March 2024
- 174 Pages
Global
From €6655EUR$7,500USD£5,761GBP
- Report
- February 2024
- 200 Pages
Global
From €6655EUR$7,500USD£5,761GBP
- Report
- November 2023
- 30 Pages
Global
From €2884EUR$3,250USD£2,496GBP
- Report
- May 2023
- 200 Pages
Global
From €6655EUR$7,500USD£5,761GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2884EUR$3,250USD£2,496GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2884EUR$3,250USD£2,496GBP
From €3106EUR$3,500USD£2,688GBP
From €3106EUR$3,500USD£2,688GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3106EUR$3,500USD£2,688GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3106EUR$3,500USD£2,688GBP
- Report
- January 2025
- 185 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- January 2025
- 185 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3549EUR$4,000USD£3,073GBP
- Report
- January 2025
- 140 Pages
Europe
From €3549EUR$4,000USD£3,073GBP
- Report
- January 2025
- 185 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- December 2024
- 85 Pages
Spain
From €3106EUR$3,500USD£2,688GBP
- Report
- December 2024
- 87 Pages
Spain
From €3106EUR$3,500USD£2,688GBP
- Report
- December 2024
- 186 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- November 2024
- 183 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- November 2024
- 180 Pages
Global
From €3993EUR$4,500USD£3,457GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more